Supernus (SUPN) | Stock Overview & Key Data
Supernus Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $61.25 on June 25, 2018
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Supernus SUPN | 1.77B Small-cap | -0.22% | -5.47% | -2.54% | -15.98% | -13.67% | 22.86% | 6.07% | 31.88% |
| Zoetis ZTS | 70.27B Large-cap | 2.18% | -6.53% | -0.27% | -2.53% | -2.11% | -9.02% | -10.56% | 16.11% |
| Haleon Plc - ADR HLN | 47.20B Large-cap | -2.12% | -6.71% | 9.49% | 7.29% | 7.52% | 21.02% | 38.33% | 38.33% |
| Indivior PLC INDV | 1.75B Small-cap | 5.50% | 15.79% | 65.60% | 25.40% | 24.40% | 2.05% | 316.49% | 1,340.19% |
| Bausch Health BHC | 2.26B Mid-cap | 3.15% | 41.36% | 30.61% | -12.48% | -13.48% | -2.35% | -19.22% | -58.93% |
| Ani Pharmaceuticals ANIP | 1.43B Small-cap | -0.52% | 2.74% | -3.10% | 19.36% | 17.08% | 6.25% | 107.57% | 139.74% |
Ownership & Short Interest
Supernus Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Supernus would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
In the last 52 weeks, Supernus reached a high of $40.28 (on February 5, 2025) and a low of $25.94 (on July 8, 2024).
Curious about Supernus's size and valuation? Its market capitalization stands at 1.77B. When it comes to valuation, the P/E ratio (trailing twelve months) is 28.53, and the forward P/E (looking ahead) is 16.76.
As for dividends, Supernus isn't currently offering a significant yield, or that specific data isn't available right now.
When looking at Supernus, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS70.27B Healthcare Drug Manufacturers - Specialty & Generic -9.02% -10.56% Haleon Plc - ADR
HLN47.20B Healthcare Drug Manufacturers - Specialty & Generic 21.02% 38.33% Indivior PLC
INDV1.75B Healthcare Drug Manufacturers - Specialty & Generic 2.05% 316.49% Bausch Health
BHC2.26B Healthcare Drug Manufacturers - Specialty & Generic -2.35% -19.22% Ani Pharmaceuticals
ANIP1.43B Healthcare Drug Manufacturers - Specialty & Generic 6.25% 107.57% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
To get a sense of Supernus's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 6.32%, the Debt to Equity ratio from the most recent quarter is 3.13, and its Gross Profit Margin stands at 89.48%.
Looking at Supernus's growth, its revenue over the trailing twelve months (TTM) was $668M. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.30%, and quarterly earnings saw a YoY growth of 4.30%.
Wondering who owns Supernus stock? Company insiders (like executives and directors) hold about 4.87% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 109.18%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.